Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 79

Results For "National"

2148 News Found

Strides secures shareholders approval for OneSource CDMO
News | September 12, 2024

Strides secures shareholders approval for OneSource CDMO

The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE


Briefs: Medicamen Biotech, Aurobindo Pharma and Ajooni Biotech
News | September 12, 2024

Briefs: Medicamen Biotech, Aurobindo Pharma and Ajooni Biotech

The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility


Ayush Ministry resolves 1346 Public Grievances under the Special Campaign 3.0
News | September 12, 2024

Ayush Ministry resolves 1346 Public Grievances under the Special Campaign 3.0

Secretary Vaidya Rajesh Kotecha has urged senior officials to strive for the successful attainment of targets during the campaign


NHA and IIT Kanpur sign MoU for development of digital public goods for AI in healthcare
Digitisation | September 11, 2024

NHA and IIT Kanpur sign MoU for development of digital public goods for AI in healthcare

The partnership aims to revolutionize Artificial Intelligence in health research with innovative data platform


Health Ministry releases
Policy | September 10, 2024

Health Ministry releases "Health Dynamics of India (Infrastructure and Human Resources) 2022-23"

The publication serves as a foundational tool for identifying gaps and addressing needs in various areas, including rural, urban, and tribal regions


Atal Innovation Mission, NITI Aayog hosts 20th MedTech Mitra Technical advisory meeting
Policy | September 10, 2024

Atal Innovation Mission, NITI Aayog hosts 20th MedTech Mitra Technical advisory meeting

MedTech Mitra initiative aims to empower MedTech innovators and advance healthcare solutions


Datopotamab deruxtecan showed median overall survival of 14.6 months in TROPION-Lung01 Phase III trial
Clinical Trials | September 10, 2024

Datopotamab deruxtecan showed median overall survival of 14.6 months in TROPION-Lung01 Phase III trial

TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population


Aster Health Academy to offer advanced medical courses
News | September 10, 2024

Aster Health Academy to offer advanced medical courses

The collaborations will help curate industry focused courses such as Advanced Certification courses for healthcare professionals in Healthcare Marketing, Healthcare Technology and Specialized Clinical Fellowship Level programs with university accreditation


Combination of ‘Siddha’ drugs reduces anemia in adolescent girls: Study
News | September 10, 2024

Combination of ‘Siddha’ drugs reduces anemia in adolescent girls: Study

The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme


Ifinatamab Deruxtecan continues to demonstrate promising response rates for lung cancer in Phase 2 Trial
Clinical Trials | September 09, 2024

Ifinatamab Deruxtecan continues to demonstrate promising response rates for lung cancer in Phase 2 Trial

Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients